| 摘要 |
<P>PROBLEM TO BE SOLVED: To provide an insulin-like growth factor 1 (IGF1) molecule stable and available for a longer period of time in vivo than a naturally occurring molecule. <P>SOLUTION: A fusion protein comprises an IGF1 variant component and a fusion component (F), and, optionally, a signal sequence, exhibits improved stability relative to a native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, a targeting ligand, or another active or therapeutic compound. The IGF1 variants have improved ability to induce skeletal muscle hypertrophy relative to the native IGF1. <P>COPYRIGHT: (C)2012,JPO&INPIT |
